Financials data is unavailable for this security.
View more
Year on year Arecor Therapeutics PLC grew revenues 90.30% from 2.40m to 4.57m while net income improved from a loss of 9.26m to a smaller loss of 8.55m.
Gross margin | -- |
---|---|
Net profit margin | -176.89% |
Operating margin | -184.81% |
Return on assets | -56.84% |
---|---|
Return on equity | -94.76% |
Return on investment | -89.06% |
More ▼
Cash flow in GBPView more
In 2023, Arecor Therapeutics PLC increased its cash reserves by 6.88%, or 328.00k. Cash Flow from Investing totalled 6.52m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 5.84m for operations while cash used for financing totalled 180.00k.
Cash flow per share | -0.2692 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.1658 |
---|---|
Tangible book value per share | 0.0604 |
More ▼
Balance sheet in GBPView more
Current ratio | 1.37 |
---|---|
Quick ratio | 1.27 |
Total debt/total equity | 0.0551 |
---|---|
Total debt/total capital | 0.0523 |
More ▼